Oral acyclovir in acute herpes zoster

Area of Science:

• Virology
• Dermatology
• Clinical Pharmacology

Background:

• Herpes zoster (shingles) is a viral infection causing painful rashes.
• Effective antiviral treatments are crucial for managing herpes zoster, especially in elderly populations.

Purpose of the Study:

• To evaluate the efficacy and safety of oral acyclovir in treating herpes zoster in elderly, immunocompetent patients.
• To assess the impact of acyclovir on lesion progression and pain management.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 205 elderly patients with herpes zoster.
• Patients received oral acyclovir (800 mg, five times daily for seven days) or placebo, initiated within 72 hours of rash onset.

Main Results:

• Acyclovir significantly accelerated the arrest of new lesion formation, vesicle loss, and full crusting (p < 0.05) in patients treated within 48 hours.
• Significant pain reduction was observed in the acyclovir group compared to placebo (p = 0.008).
• 40% of severe pain patients on acyclovir reported no/mild pain post-treatment versus 0% on placebo (p < 0.001).

Conclusions:

• Oral acyclovir is effective in modifying acute herpes zoster progression.
• Acyclovir demonstrates significant pain-relieving benefits in herpes zoster patients.
• The treatment was well-tolerated with no clinically significant adverse effects observed.